Literature DB >> 28895166

Diabetes insipidus after discontinuation of vasopressin infusion for septic shock.

H Rana1,2, N Ferguson3, P V Dicpinigaitis1,2.   

Abstract

WHAT IS KNOWN AND
OBJECTIVE: Despite widespread use of vasopressin for the treatment of septic shock, few cases of diabetes insipidus (DI) following its discontinuation have been reported. CASE
SUMMARY: A 54-year-old man presented with pneumonia progressing to septic shock, requiring norepinephrine and vasopressin for refractory hypotension. After clinical improvement, the patient on 3 separate occasions developed polyuria and severe hypernatremia upon discontinuation of vasopressin, with prompt recovery upon its resumption. WHAT IS NEW AND
CONCLUSION: Occurrence of DI upon discontinuation of vasopressin infusion appears to be rare, but incidence may be underestimated due to a paucity of published reports. Actual incidence and underlying mechanism of this phenomenon remain to be elucidated.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  desmopressin; diabetes insipidus; hypernatremia; septic shock; vasopressin

Mesh:

Substances:

Year:  2017        PMID: 28895166     DOI: 10.1111/jcpt.12627

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  3 in total

1.  Diabetes Insipidus After Discontinuation of Vasopressin Infusion for Treatment of Shock.

Authors:  Hannah Ferenchick; Nail Cemalovic; Nadia Ferguson; Peter V Dicpinigaitis
Journal:  Crit Care Med       Date:  2019-12       Impact factor: 7.598

2.  Why So Salty? Transient Diabetes Insipidus After Discontinuation of Vasopressin.

Authors:  Jacqueline A Urban; Francis Zirille; Tyree H Kiser; Yael Aschner
Journal:  Ann Intern Med Clin Cases       Date:  2022-06-07

3.  Transient Central Diabetes Insipidus after Discontinuation of Vasopressin.

Authors:  Nathaniel Carman; Carl Kay; Abigail Petersen; Maria Kravchenko; Joshua Tate
Journal:  Case Rep Endocrinol       Date:  2019-12-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.